STARD4-AS1 promotes coronary artery disease and modulates endothelial dysfunction by targeting miR-204-3p/FLI1.
TL;DR
STARD4-AS1 can regulate endothelial cell functions under hypoxic conditions and has the potential as a novel therapeutic target and a promising circulating biomarker candidate for CAD.
OpenAlex 토픽 ·
interferon and immune responses
Lipid metabolism and disorders
Congenital heart defects research
STARD4-AS1 can regulate endothelial cell functions under hypoxic conditions and has the potential as a novel therapeutic target and a promising circulating biomarker candidate for CAD.
APA
Yuan Li, Li. Liu (2026). STARD4-AS1 promotes coronary artery disease and modulates endothelial dysfunction by targeting miR-204-3p/FLI1.. Microvascular research, 165, 104919. https://doi.org/10.1016/j.mvr.2026.104919
MLA
Yuan Li, et al.. "STARD4-AS1 promotes coronary artery disease and modulates endothelial dysfunction by targeting miR-204-3p/FLI1.." Microvascular research, vol. 165, 2026, pp. 104919.
PMID
41707955
Abstract
[BACKGROUND] Coronary artery disease (CAD) remains the primary cause of mortality and disability-adjusted life years lost worldwide. This study focuses on elucidating the expression, cell functions, and possible regulatory mechanisms of the steroidogenic acute regulator protein-related lipid transfer domain containing 4-antisense RNA 1 (STARD4-AS1) in CAD.
[METHODS] GSE113079 dataset was used to identify the studied lncRNA. Serum STARD4-AS1 levels were quantified by RT-qPCR in a cohort of 88 CAD patients and 72 healthy participants. In vitro functional assays were performed in human primary coronary artery endothelial cells (HCAECs) under hypoxia following transfection with STARD4-AS1 siRNA. The cell function assays encompassed monocyte adhesion, lactate dehydrogenase (LDH) release, and the levels of malondialdehyde (MDA), superoxide dismutase (SOD), and low-density lipoprotein cholesterol (LDL-C). A downstream miRNA for STARD4-AS1 was predicted and validated via dual-luciferase reporter assays. Rescue experiments were conducted for the function assays of STARD4-AS1/miRNA axis.
[RESULTS] GSE113079 dataset revealed a significant elevation of STARD4-AS1 in CAD peripheral blood mononuclear cells. In CAD serum, STARD4-AS1 level was elevated. The STARD4-AS1 upregulation was positively correlated with LDL-C levels and had a diagnostic value for CAD. Under hypoxia, the knockdown of STARD4-AS1 mitigated the LDH release, MDA levels, the intracellular LDL-C content, and monocyte adhesion to HCAECs. MiR-204-3p was identified as a target miRNA for STARD4-AS1, while Friend leukemia virus integration 1 (FLI1) was a target gene for miR-204-3p. MiR-204-3p inhibition can offset the functions of STARD4-AS1 suppression on HCAECs exposed to hypoxic conditions.
[CONCLUSION] STARD4-AS1 can regulate endothelial cell functions under hypoxic conditions. This study highlights its potential as a novel therapeutic target and a promising circulating biomarker candidate for CAD.
[METHODS] GSE113079 dataset was used to identify the studied lncRNA. Serum STARD4-AS1 levels were quantified by RT-qPCR in a cohort of 88 CAD patients and 72 healthy participants. In vitro functional assays were performed in human primary coronary artery endothelial cells (HCAECs) under hypoxia following transfection with STARD4-AS1 siRNA. The cell function assays encompassed monocyte adhesion, lactate dehydrogenase (LDH) release, and the levels of malondialdehyde (MDA), superoxide dismutase (SOD), and low-density lipoprotein cholesterol (LDL-C). A downstream miRNA for STARD4-AS1 was predicted and validated via dual-luciferase reporter assays. Rescue experiments were conducted for the function assays of STARD4-AS1/miRNA axis.
[RESULTS] GSE113079 dataset revealed a significant elevation of STARD4-AS1 in CAD peripheral blood mononuclear cells. In CAD serum, STARD4-AS1 level was elevated. The STARD4-AS1 upregulation was positively correlated with LDL-C levels and had a diagnostic value for CAD. Under hypoxia, the knockdown of STARD4-AS1 mitigated the LDH release, MDA levels, the intracellular LDL-C content, and monocyte adhesion to HCAECs. MiR-204-3p was identified as a target miRNA for STARD4-AS1, while Friend leukemia virus integration 1 (FLI1) was a target gene for miR-204-3p. MiR-204-3p inhibition can offset the functions of STARD4-AS1 suppression on HCAECs exposed to hypoxic conditions.
[CONCLUSION] STARD4-AS1 can regulate endothelial cell functions under hypoxic conditions. This study highlights its potential as a novel therapeutic target and a promising circulating biomarker candidate for CAD.
MeSH Terms
Coronary Artery Disease; Membrane Transport Proteins; Humans; Male; Female; Middle Aged; Aged; Datasets as Topic; MicroRNAs; Proto-Oncogene Protein c-fli-1; Leukocytes, Mononuclear; L-Lactate Dehydrogenase; Malondialdehyde; Superoxide Dismutase; Cholesterol, LDL; Endothelial Cells; RNA, Long Noncoding; Oxidative Stress; Hypoxia
같은 제1저자의 인용 많은 논문 (5)
- The efficacy of botulinum toxin type A treatment and surgery for acute acquired comitant esotropia.
- Botulinum toxin A (BoNT/A) for the treatment of depression: A randomized, double-blind, placebo, controlled trial in China.
- Hyaluronic Acid Compound Filling Plus Mesotherapy vs Botulinum Toxin A for the Treatment of Horizontal Neck Lines: A Multicenter, Randomized, Evaluator-Blinded, Prospective Study in Chinese Subjects.
- Correction to: Hyaluronic Acid Compound Filling Plus Mesotherapy vs Botulinum Toxin A for the Treatment of Horizontal Neck Lines: A Multicenter, Randomized, Evaluator-Blinded, Prospective Study in Chinese Subjects.
- The use of botulinum toxin A in upper lip augmentation.